Dry Eye

Several presentations at ASCRS 2026 spotlight faster dry eye relief and smarter pre-operative care, showing lifitegrast and new drugs can ease symptoms quickly and improve cataract biometry.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

Previously, the company had received CRLs from the FDA in April 2025 and November 2023 for NDAs for reproxalap for the treatment of dry eye.

The planned study will assess the safety, efficacy, and optimal dosing of the investigational therapy in approximately 150 patients with DED

Ophthalmologists report dry eye’s mixed mechanisms, symptom-driven diagnosis, uneven treatment response, and payer hurdles—what needs fixing next.

Interventional therapies give patients faster relief and better vision outcomes

Dry eye care shifts to spectrum-based screening and targeted therapies, from TRPM8 agonists to evaporation shields, with upcoming anti-inflammatories promising faster relief.

New research compares 7 HA dry eye drops; Ivizia and Thealoz Duo most closely match natural tear viscosity during blinking.

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, AMD, and rare eye diseases.

An in-depth look at the FDA approvals and clinical milestones that defined 2025 and how they are poised to influence practice patterns moving into 2026.

An overview of the top 10 stories from Optometry Times in 2025.

Panel examines drug mechanisms, patient factors, and strategies to optimize results.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The company plans to submit its NDA package in the second half of 2026.

The grading scales were compiled with the goals of achieving conciseness and the ability to provide clear drug-dose-modification recommendations compared with the previous ocular CTCAE scale.

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics natural tears and restores tear-film balance."

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator to increase tear production in patients whose tear production is thought to be reduced due to ocular inflammation associated with dry eye syndrome.

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

Researchers analyze the DREAM study, revealing lid margin collarettes in dry eye patients and their surprising lack of progression over time.

Ophthalmologists weigh in on evolving diagnostic tools, emerging therapies, and practical approaches for managing today’s most challenging ocular-surface cases.

Host Deborah Ristvedt, DO, is joined by Marguerite B. McDonald, MD, FACS, to discuss her journey with pioneering contributions to ophthalmology, patient-centered care, leadership, and guidance for the next generation.